Suven Life Sciences gets three patents
The patents have been received in Canada, China and India.
New Delhi, January 31, 2014: Suven Life has received three product patents in Canada, China and India for its new chemical entities for treatment of disorders associated with neurodegenerative diseases.
The granted claims of the patents include the class of selective 5-HT compounds discovered by Suven and these patents are valid through 2025. It may be noted here that the new chemical entities are being developed as therapeutic agents and are useful in treatment of cognitive impairment associated with neurodegenerative diseases such as Alzheimer's disease, attention deficient hyperactivity disorder (ADHD), Huntington's disease, Parkinson and Schizophrenia.
The company believed that these areas have high unmet medical need with a huge market potential globally. With these new patents, the company now has a total of 14 granted patents from Canada, 12 from China and 17 from India.
The company also said in a statement that products out of these inventions can be out-licensed at various phases of clinical development.